289 related articles for article (PubMed ID: 35572596)
21. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
Pham MM; Hinchcliff E; Avila M; Westin SN
Cancer J; 2021 Nov-Dec 01; 27(6):491-500. PubMed ID: 34904812
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
Chu YY; Yam C; Yamaguchi H; Hung MC
J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
[TBL] [Abstract][Full Text] [Related]
23. Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms.
Garzón-Hernández C; Ramírez-Merino N; Soberon MCM
Arch Med Res; 2022 Dec; 53(8):807-817. PubMed ID: 36460545
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of PARP inhibitor sensitivity and resistance.
D'Andrea AD
DNA Repair (Amst); 2018 Nov; 71():172-176. PubMed ID: 30177437
[TBL] [Abstract][Full Text] [Related]
25. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Peyraud F; Italiano A
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526888
[TBL] [Abstract][Full Text] [Related]
26. Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Andronikou C; Rottenberg S
Trends Mol Med; 2021 Jul; 27(7):630-642. PubMed ID: 34030964
[TBL] [Abstract][Full Text] [Related]
27. A New Opportunity for "Old" Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism.
Iglesias P; Seoane M; Golán-Cancela I; Fraga M; Arce VM; Costoya JA
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240195
[TBL] [Abstract][Full Text] [Related]
28. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
Chiappa M; Guffanti F; Bertoni F; Colombo I; Damia G
Drug Resist Updat; 2021 Mar; 55():100744. PubMed ID: 33551306
[TBL] [Abstract][Full Text] [Related]
29. Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways.
Seo Y; Tamari K; Takahashi Y; Minami K; Tatekawa S; Isohashi F; Suzuki O; Akino Y; Ogawa K
Int J Radiat Biol; 2022; 98(7):1222-1234. PubMed ID: 34919022
[TBL] [Abstract][Full Text] [Related]
30. PARP Inhibitors in Cancer Diagnosis and Therapy.
Chan CY; Tan KV; Cornelissen B
Clin Cancer Res; 2021 Mar; 27(6):1585-1594. PubMed ID: 33082213
[TBL] [Abstract][Full Text] [Related]
31. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
32. Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies.
Li T; Wang X; Qin S; Chen B; Yi M; Zhou J
Biomed Pharmacother; 2023 Jun; 162():114712. PubMed ID: 37075667
[TBL] [Abstract][Full Text] [Related]
33. Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in
Li P; Zhen Y; Kim C; Liu Z; Hao J; Deng H; Deng H; Zhou M; Wang XD; Qin T; Yu Y
Sci Adv; 2023 Oct; 9(43):eadg7752. PubMed ID: 37878693
[TBL] [Abstract][Full Text] [Related]
34. Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
Franzese O; Graziani G
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428727
[TBL] [Abstract][Full Text] [Related]
35. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
36. PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response.
Wurster S; Hennes F; Parplys AC; Seelbach JI; Mansour WY; Zielinski A; Petersen C; Clauditz TS; Münscher A; Friedl AA; Borgmann K
Oncotarget; 2016 Mar; 7(9):9732-41. PubMed ID: 26799421
[TBL] [Abstract][Full Text] [Related]
37. Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.
Wang P; Zhu WT; Wang Y; Song SS; Xi Y; Yang XY; Shen YY; Su Y; Sun YM; Gao YL; Chen Y; Ding J; Miao ZH; Zhang A; He JX
Eur J Med Chem; 2023 Nov; 259():115709. PubMed ID: 37567056
[TBL] [Abstract][Full Text] [Related]
38. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.
Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY
J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182
[TBL] [Abstract][Full Text] [Related]
39. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
40. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]